Increased lithium levels in water could increase the risk of autism.

Published Date: 05 Apr 2023

A new study led by a UCLA Health researcher found that pregnant women had a slightly increased risk of having children with autism spectrum disorder if the household tap water had higher lithium levels.

Read Full News

Latest News



Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Growing Role of AI in Cancer Treatment

2.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant

3.

Mapping lifelong chronic health risks for childhood cancer survivors

4.

AI-based liquid biopsy shows promise for detecting brain cancer

5.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot